Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

October 27, 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

October 27, 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

October 20, 2022

Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.

October 10, 2022

Dr Brentjens discussed targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.

October 10, 2022

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

October 03, 2022

MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.

October 03, 2022

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

June 23, 2022

Eunice Wang, MD, discusses the long-term results of a phase 2 trial investigating crenolanib plus chemotherapy in adult patients with newly diagnosed FLT3-mutant acute myeloid leukemia.

May 09, 2022

Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.

April 25, 2022

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

April 10, 2022

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

February 11, 2022

The utilization of monoclonal antibodies such as nivolumab and Ipilimumab have become vital in shifting the treatment paradigm in gastroesophageal and gastrointestinal cancers.

February 10, 2022

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.

February 09, 2022

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

January 28, 2022

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

January 26, 2022

Neoadjuvant chemosensitivity was associated with an improvement in overall survival following adjuvant chemotherapy in patients with resectable gastric cancer, according to findings from a cohort study that were published in JAMA Network Open.

January 26, 2022

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

January 25, 2022

The combination of tivozanib and durvalumab showcased early efficacy with a manageable safety profile in patients with previously untreated advanced hepatocellular carcinoma.

January 25, 2022

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.

January 24, 2022

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.